Patents by Inventor Phillip Cook

Phillip Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220318650
    Abstract: Provided are methods and systems for computational quantification of an entity's affinity to a qualitative issue defined with Boolean data in a computing system. The disclosed invention provides for a system for rating a first entity's affinity to an issue through information provided by the entity itself, or derived from information provided by other entities related to the first entity. Further, a first entity's affinity to a group of political issues defined as an umbrella issue can also be rated. With the present system, qualitative data is utilized to quantify an entity's affinity to a topic or issue.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 6, 2022
    Inventors: Ryan Scott Cook, Andrew Phillip Groff
  • Publication number: 20220289721
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 15, 2022
    Applicant: Array BioPharma Inc.
    Inventors: Patrick Michael BARBOUR, Katie Keaton BROWN, Adam Wade COOK, Erik James HICKEN, Dean Russell KAHN, Ellen Ruth LAIRD, Andrew Terrance METCALF, David Austin MORENO, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Brett Joseph PRIGARO, Li REN, Eugene TARLTON
  • Patent number: 11414404
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 16, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
  • Publication number: 20080032945
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2?-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.
    Type: Application
    Filed: June 15, 2007
    Publication date: February 7, 2008
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Cook, Andrew Kawasaki
  • Publication number: 20070275912
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: December 21, 2006
    Publication date: November 29, 2007
    Inventors: Balkrishen Bhat, Anne Eldrup, Thazha Prakash, Phillip Cook, Robert LeFemina, Amy Simcoe, Carrie Rutkowski, Mario Valenciano
  • Publication number: 20070265224
    Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Application
    Filed: June 14, 2007
    Publication date: November 15, 2007
    Inventors: Phillip Cook, Guangyi Wang, Thomas Bruice, Nicholas Boyle, Janet Leeds, Jennifer Brooks, Marija Prhavc, Maria Ariza, Patrick Fagan, Yi Jin, Vivek Rajwanshi, Kathleen Tucker
  • Publication number: 20070259832
    Abstract: The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    Type: Application
    Filed: June 14, 2007
    Publication date: November 8, 2007
    Inventors: Phillip Cook, Guangyi Wang, Thomas Bruice, Nicholas Boyle, Janet Leeds, Jennifer Brooks, Marija Prhavc, Maria Ariza, Patrick Fagan, Yi Jin, Vivek Rajwanshi, Kathleen Tucker
  • Publication number: 20070249551
    Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.
    Type: Application
    Filed: September 28, 2005
    Publication date: October 25, 2007
    Inventors: Ching-Leou Teng, Phillip Cook, Lloyd Tillman, Gregory Hardee, David Ecker, Muthiah Manoharan
  • Publication number: 20070232798
    Abstract: Oligonucleotide analogs are disclosed having pyrimidine monomeric sub-units therein that are modified at the 2? and 5? positions. Monomeric sub-units having these modifications may be further modified at the 2? position. Improved processes for the synthesis of 2?-O-substituted pyrimidine nucleosides are also provided. The processes feature alkylation of a 2,2?-anhydropyrimidine nucleoside or a 2S,2?-anhydropyrimidine nucleoside with a weak nucleophile in the presence of a Lewis acid.
    Type: Application
    Filed: March 12, 2007
    Publication date: October 4, 2007
    Inventors: Phillip Cook, Yogesh Sanghvi, Kelly Sprankle, Bruce Ross, Rich Griffey, Robert Springer
  • Publication number: 20070141203
    Abstract: The present invention relates to beverage compositions that have the added benefit of providing a water-soluble source of Vitamin E. For example, d,l- or d-?-tocopheryl polyethylene glycol 1000 succinate (such as Vitamin E TPGSā„¢) may be used to provide tocopheryl (i.e., vitamin E) content to beverages while concurrently maintaining beverage clarity when desired. Various additives may also be used in the beverage compositions of the present invention, such as flavoring agents, colorants, preservatives, sweeteners as well as other vitamins, minerals and/or electrolytes.
    Type: Application
    Filed: February 12, 2007
    Publication date: June 21, 2007
    Inventor: Phillip Cook
  • Publication number: 20070135363
    Abstract: Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.
    Type: Application
    Filed: February 14, 2007
    Publication date: June 14, 2007
    Applicant: BIOTA, INC.
    Inventors: Phillip Cook, Gregory Ewing, Deborah Ewing, Yi Jin, John Lambert, Marija Prhavc, Vasanthankumar Rajappan, Vivek Rajwanshi, Kandasamy Sakthivel
  • Publication number: 20070123702
    Abstract: Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance. By utilizing C2? endo sugars or O4? endo sugars, the B-form characteristics are imparted to a portion of the oligonucleotide. The A-form characteristics are imparted via use of either 2?-O-modified nucleotides that have 3? endo geometries or use of end caps having particular nuclease stability or by use of both of these in conjunction with each other.
    Type: Application
    Filed: November 17, 2005
    Publication date: May 31, 2007
    Inventors: Muthiah Manoharan, Venkatraman Mohan, Phillip Cook, Andrew Kawasaki
  • Publication number: 20070104850
    Abstract: The present invention provides a process for producing a solid sucrose acetate isobutyrate (SAIB) formulation, by combining sucrose acetate isobutyrate in an amount from about 1 weight percent to about 80 weight percent based on the total weight percent of the total solid formulation; and a solid substrate that is soluble in water or oil, wherein the substrate is present in an amount from about 99 weight percent to about 30 weight percent based on the weight of the formulation, wherein the formulation produced is pourable in less than about 20 seconds according to ASTM method D1895-96. The solid SAIB formulation is useful in beverage applications.
    Type: Application
    Filed: December 20, 2006
    Publication date: May 10, 2007
    Inventors: Phillip Cook, George Zima, Danessa Sexton
  • Publication number: 20070032598
    Abstract: Disclosed are thermally-stable, anthraquinone colorant compounds (dyes) which contain one or more vinyl groups which render the compounds copolymerizable with reactive vinyl monomers to produce colored, polymeric compositions such as acrylate and methacrylate polymeric materials. The compounds possess good fastness (stability) to ultraviolet (UV) light, good solubility in vinyl monomers, good color strength and excellent thermal stability. Also disclosed are (1) coating composition comprising (i) one or more polymerizable vinyl compounds, (ii) one or more of the dye compounds described above, and (iii) a photoinitiator and (2) polymeric materials, i.e., polymers derived from one or more acrylic acid esters, one or more methacrylic acid esters, one or more other polymerizable vinyl compounds or mixtures of any two or more thereof, having copolymerized therein one or more of the anthraquinone colorant compounds.
    Type: Application
    Filed: October 6, 2006
    Publication date: February 8, 2007
    Inventors: Michael Cyr, Max Weaver, Gerry Rhodes, Jason Pearson, Phillip Cook, Jos De Wit, Larry Johnson
  • Publication number: 20070032446
    Abstract: Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2?-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.
    Type: Application
    Filed: July 14, 2006
    Publication date: February 8, 2007
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Cook, Brett Monia
  • Publication number: 20060270624
    Abstract: Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and sub-sequences of 2?-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.
    Type: Application
    Filed: July 14, 2006
    Publication date: November 30, 2006
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Cook, Brett Monia
  • Publication number: 20060264390
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: July 31, 2006
    Publication date: November 23, 2006
    Inventors: Anne Eldrup, Marija Prhavc, Phillip Cook, Steven Carroll, David Olsen
  • Publication number: 20060205686
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: September 27, 2005
    Publication date: September 14, 2006
    Inventors: Balkrishen Bhat, Anne Eldrup, Thazha Prakash, Phillip Cook, Steven Carroll, Malcolm MacCoss, David Olsen
  • Publication number: 20060052469
    Abstract: Disclosed are novel colorant compounds which contain one or more ethylenically-unsaturated (vinyl), photopolymerizable radicals which may be copolymewrized (or cured) with ethylenically-unsaturated monomers to produce colored compositions such as colored acrylic coatings and polymers, e.g., coatings and polymers produced from acrylate and methacrylate esters, colored polystyrenes, and similar colored polymeric materials derived from other ethylenically-unsaturated monomers. The present invention also pertains to processes for the preparation of certain of the photopolymerizable colorant compounds.
    Type: Application
    Filed: October 13, 2005
    Publication date: March 9, 2006
    Inventors: Michael Cyr, Max Weaver, Gerry Rhodes, Jason Pearson, Phillip Cook
  • Publication number: 20060052589
    Abstract: Disclosed are novel colorant compounds which contain one or more ethylenically-unsaturated (vinyl), photopolymerizable radicals which may be copolymewrized (or cured) with ethylenically-unsaturated monomers to produce colored compositions such as colored acrylic coatings and polymers, e.g., coatings and polymers produced from acrylate and methacrylate esters, colored polystyrenes, and similar colored polymeric materials derived from other ethylenically-unsaturated monomers. The present invention also pertains to processes for the preparation of certain of the photopolymerizable colorant compounds.
    Type: Application
    Filed: October 13, 2005
    Publication date: March 9, 2006
    Inventors: Michael Cyr, Max Weaver, Gerry Rhodes, Jason Pearson, Phillip Cook